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Purpose: To report crystal formation as a complication of intravitreal ganciclovir injection.
Patients and methods: A 73-year-old female patient with unilateral cytomegalovirus retinitis 
was treated with intravitreous ganciclovir (4 mg/0.04 mL).
Results: After the intravitreal injection, sudden crystallization was observed in the vitreous 
humor. The patient experienced marked reduction in visual acuity and increased intraocular 
pressure. Despite aqueous paracenthesis and pars plana vitrectomy, optic atrophy was observed 
and her visual acuity remained unimproved after 12 months.
Conclusion: Crystal formation can occur as a complication of intravitreal ganciclovir injec-
tion. Associated retinal and optic nerve damage was found which results in permanent visual 
morbidity.
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Introduction
Ganciclovir is an antiviral drug developed by Kelvin K Ogilvie in 1982 to use against 
herpesviruses.1 Dry ganciclovir powder should be completely reconstituted by sterile 
water before use. Systemic administration of ganciclovir is an effective therapeutic 
and preventative strategy for cytomegalovirus (CMV) retinitis.1–3 However, parenteral 
ganciclovir can cause serious toxicity including neutropenia, thrombocytopenia, 
anemia, phlebitis, and gastrointestinal disturbances.4 Therefore, local intraocular 
ganciclovir therapy had been introduced and widely used for patients who could not 
tolerate systemic treatment.5–7 The efficacy of local administration is comparable to 
systemic ganciclovir while the adverse effect is less.5–7 The known side effects of 
intravitreal injection are mostly related to the procedure rather than the drug itself 
including retinal detachment, vitreous hemorrhage, endophthalmitis, and cataract.5–7 
Here, we first report a crystal formation as a rare unfavorable condition from intravitreal 
ganciclovir injection.
Material and methods
Case report
A 73-year-old Asian female patient presented with a history of chronic anterior uveitis 
and secondary increased intraocular pressure (IOP) in the right eye for 5 years. Her 
visual acuity was 6/24 and 6/9 in the right and left eye respectively. Intraocular pres-
sures were 16 and 18 mmHg in the right and left eye, respectively, with antiglaucoma 
drugs including timolol maleate 0.5% and brimonidine tartrate 0.15% eyedrops. Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Slit lamp biomicroscopic examination demonstrated 2+ cells 
in the anterior chamber and an area of iris atrophy in her 
right eye. Fundoscopic examination showed inferotemporal 
retinal perivascular infiltration. Her complete blood count and 
chest X-ray were within normal limits. The purified protein 
derivative skin test, Veneral Disease Research Laboratory 
test, treponema pallidum hemagglutination test, and anti-
HIV were all negative. Topical steroid eyedrop and systemic 
immunosuppressive therapy (prednisolone acetate 1% and 
methotrexate) were attempted without success.
A diagnostic aqueous paracenthesis was performed. 
Cytomegalovirus DNA was detected by polymerase chain 
reaction whereas herpes simplex and varicella zoster virus 
DNA was not found. A diagnosis of CMV retinitis was 
made. The options of systemic or local ganciclovir were 
considered. Because of the patient’s advanced age and the 
unilateral involvement of the disease, local was chosen over 
systemic administration.
A therapeutic intravitreal injection of uniformly dissolved 
ganciclovir (4 mg/0.04 mL) was given to the right eye. Sud-
denly after the procedure, crystal formation was observed 
in the vitreous humor anterior to the optic disc (Figure 1). 
Concomitantly, the patient complained of sudden decreased 
vision and the IOP rose to 33 mmHg in her right eye.
To treat the complication emergently, 0.1 mL of aqueous 
humor was immediately released resulting in the reduction 
of IOP to 14 mmHg. In addition, topical timolol maleate 
0.5% and oral acetazolamide were administered. Despite the 
therapeutic procedures, the patient’s visual acuity diminished 
to finger count at 1 foot. A fundoscopic examination showed 
retinal edema and cherry red spot in the macular region. 
A fundus fluorescein angiogram revealed delayed arm to 
retina time, cystoid macular edema, and late vascular leak-
age of the papillomacular bundle. A diagnosis of ganciclovir 
toxicity and associated central retinal artery occlusion was 
made. Pars plana vitrectomy was performed to remove the 
crystals along with intravitreal triamcinolone injection (0.4 
mg/0.1 mL) to treat cystoid macular edema. Two weeks after 
the last procedure, the inflammation completely subsided, the 
IOP was well controlled, macula was flattened, but the optic 
disc became subsequently pale. Unfortunately, the patient’s 
vision was not improved even after 12-month follow-up.
Discussion
Ganciclovir is an antiviral agent approved by United States 
Food and Drug Administration in 1989 to treat and prevent 
CMV retinitis. It is a synthetic nucleoside analog of guanine, 
which is active against human herpesvirus family including 
CMV .1,2 After intracellular phosphorylation, the active gan-
ciclovir triphosphate inhibits replication of such viruses by 
interfering with the viral DNA synthesis.
Many routes of administration were reported for different 
uses.3 Parenteral ganciclovir is approved for induction and 
maintenance treatment of CMV retinitis in immunocompro-
mised patients.3,4 Oral ganciclovir is recommended only in 
the maintenance phase after intravenous induction therapy or 
in prophylaxis treatment of solid organ transplant patients. 
Local treatment of CMV retinitis with intravitreal implant 
or intravitreal injection was introduced as an alternative to 
save cost and lower the risk of systemic side effects such 
as granulocytopenia and thrombocytopenia. Intravitreal 
injection demonstrated comparable efficacy to parenteral 
ganciclovir to control local progression of CMV retinitis in 
treated eye.5–7 The reported adverse effects included retinal 
detachment, vitreous hemorrhage, endophthalmitis, and 
cataract. In our unreported experiences, we used this high 
concentration of ganciclovir (4 mg/0.04 mL) to treat CMV 
retinitis because of two major reasons. First, due to a lot 
of CMV retinitis patients in our service, we decided to use 
alternate weekly injection 4 mg of ganciclovir instead of 2 mg 
of ganciclovir every week to reduce the number of patients in 
the clinic. While the risk of increased IOP is associated with 
volume of fluid injection, we decided to use lower volume 
as 0.04 mL to reduce that risk. With this method, less cases 
of increased IOP occurred.
In our case, the patient is immunocompetent with evidence 
of CMV-related retinitis in the right eye. After intravitreal 
ganciclovir was introduced, rapid crystallization in the vitre-
ous humor concomitant with increase IOP occurred resulting 
in subsequent optic atrophy despite treatments. Although the 
Figure 1 Fundoscopic photograph demonstrates crystallization of ganciclovir in the 
vitreous humor.Clinical Ophthalmology
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reported dose of ganciclovir to treat CMV retinitis ranged 
from 400 mg to 2 mg, our dose of 4 mg/0.04 mL, verified to 
be effective to control CMV retinitis and low risk of retinal 
vascular occlusion by our unreported data, is about 2–10 
times doses normally used. We do speculate that such high 
drug concentrations introduced in the globe lead to sudden 
change of pH in the vitreous humor, might cause crystalliza-
tion of ganciclovir. Nevertheless the exact reason of crystal 
forming is to be explored. Furthermore, this crystallization 
could cause ganciclovir overdosage in the vitreous humor and 
be toxic to the retina. Reviews of previous   studies verified 
different concentration of intravitreal   ganciclovir treatment 
with the maximum dose of 5 mg/0.1 mL injected.5–7 They 
revealed no clinical signs of retinal or optic nerve toxicity. 
Nonetheless, in an experimental model done by Moschos 
et al, intravitreal ganciclovir   injection of 200–600 mg/0.1 mL 
caused reduced to extinguish electroretinography with 
electron microscopic degeneration of photoreceptor cells 
and optic nerve fibers.8 Beside this, the sudden changes in 
osmolarity and pH may also take a role in causing retinal 
intoxication although they were not evaluated in our case. By 
our observation, we report the first case of crystal formation 
in the vitreous humor as an unexpected event after injection 
of ganciclovir. The cause of crystal formation is unknown. 
This phenomenon subsequently leads to permanent damage 
of the retinal and optic nerve. Subsequent adverse event 
as such retinal ischemia also prevent the chance of retinal 
recovery after removal of the crystal.
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